Skip to main content
. 2022 Sep 14;130(1):15–23. doi: 10.1111/1471-0528.17288

TABLE 1.

Characteristics of study participants of the two groups at baseline

500 mg (n = 152) 1000 mg (n = 126)
Age, median (IQR) 27 (23–31) 27 (22–30)
Body mass index, median (IQR) 26 (22–32) 27 (23–33)
Pregnant with twins 2 (1%) 1 (1%)
Anaemia, n (%) 70 (46%) 66 (52%)
Education, years, median (IQR) (n) 13 (12–15) (n = 143) 13 (12–15) (n = 117)
Income, n (%) a
<AUD $40,00 39 (26%) 33 (26%)
AUD $40,000–60,000 37 (24%) 31 (25%)
AUD $60,000–80,000 18 (12%) 25 (20%)
AUD $80,000–120,000 32 (21%) 20 (16%)
>AUD $120,000 13 (9%) 5 (4%)
Unknown 13 (9%) 12 (10%)
Gestational age at screening, median (IQR)
Days 231 (210–246) 227 (210–244)
Weeks 32.9 (30.0–35.1) 32.4 (30.0–34.8)
Gestational age at first infusion, median (IQR)
Days 241 (222–255) 235 (222–253)
Weeks 34.4 (31.7–36.5) 33.6 (31.6–36.1)
Blood parameters, mean (SD) (n) or median (IQR) (n)
Haemoglobin b g/L 106 (9) (n = 152) 106 (10) (n = 126)
Ferritin microg/L 6.0 (4.0–8.0) (n = 152) 6.0 (4.0–9.0) (n = 126)
Iron micromol/L 7 (5–10) (n = 143) 7 (5–10) (n = 119)
Transferrin g/L 4.3 (4.0–5.0) (n = 143) 4.5 (4.1–5.0) (n = 119)
Transferrin saturation, (%) 6 (5–10) (n = 143) 6 (4–9) (n = 119)
MCH 28 (26–30) (n = 116) 28 (26–29) (n = 90)
Folate (serum), nmol/L 28 (21–45) (n = 116) 27 (18–41) (n = 106)
B12 (serum), pmol/L 198 (162–247) (n = 149) 202 (170–244) (n = 123)
B12 (active), pmol/L 51 (37–65) (n = 115) 49 (32–66) (n = 91)
CRP, ng/L 5.7 (2.8–11.0) (n = 131) 5.0 (2.3–10.0) (n = 113)
Supplements taken in pregnancy, n (%) a
None 27 (18%) 18 (14%)
Iron only 15 (10%) 10 (8%)
Iron + pregnancy multivitamin 16 (11%) 15 (12%)
Pregnancy multivitamin (no iron) 55 (36%) 44 (35%)
Other supplements (no iron) 18 (12%) 19 (15%)
Unknown 21 (14%) 20 (16%)
a

May not add up to 100% due to rounding.

b

Stratification variable.